Mark Redell
YOU?
Author Swipe
View article: P-1200. Real-World Utilization of Rezafungin in the Outpatient Setting
P-1200. Real-World Utilization of Rezafungin in the Outpatient Setting Open
Background Rezafungin (RZF), a novel intravenous echinocandin with an extended half-life of 152 hours, was approved in the US in 2023 for adult patients with candidemia or invasive candidiasis as a once weekly dosing regimen. This provides…
View article: Activity of rezafungin against <i>Candida auris</i>
Activity of rezafungin against <i>Candida auris</i> Open
The increasing prevalence of candidemia and invasive candidiasis infections caused by Candida auris represents a global health risk. Such infections are difficult to treat as they are often multidrug-resistant and are linked to high rates …
View article: Can Oritavancin Be Used for Treatment and/or Suppressive Antimicrobial Therapy of Bone and Joint Infections Caused by Vancomycin-resistant Enterococcus faecium?
Can Oritavancin Be Used for Treatment and/or Suppressive Antimicrobial Therapy of Bone and Joint Infections Caused by Vancomycin-resistant Enterococcus faecium? Open
Background Vancomycin-resistant enterococcus (VRE) infections pose substantial challenges for the treatment and suppression of bone and joint infections. Oritavancin, a long-acting lipoglycopeptide antibiotic, has shown promising in vitro …
View article: P-1034. Week One Outcomes of Rezafungin vs Caspofungin Treatment for Candidemia and Invasive Candidiasis (CIC): Pooled Analysis of Two Randomized Trials Exploring Optimal Echinocandin Duration
P-1034. Week One Outcomes of Rezafungin vs Caspofungin Treatment for Candidemia and Invasive Candidiasis (CIC): Pooled Analysis of Two Randomized Trials Exploring Optimal Echinocandin Duration Open
Background The Phase 2 STRIVE and Phase 3 ReSTORE trials demonstrated the efficacy and safety of rezafungin for treating CIC. With data suggesting early treatment benefit for rezafungin, possibly due to its front-loaded dosing, this pooled…
View article: Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021
Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021 Open
Background/Objectives: Meropenem–vaborbactam (MEV) and ceftazidime–avibactam (CZA) are active against “urgent threat” pathogens like carbapenem-resistant Enterobacterales (CRE). However, few studies have compared outcomes between them. Met…
View article: Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement
Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement Open
Oritavancin demonstrated a significantly higher rate of clinical success compared to daptomycin, with lower all-cause and infection-related readmissions, reduced need for repeat surgical debridement, and fewer additional antibiotic require…
View article: 2816. Comparative Effectiveness of Meropenem/Vaborbactam vs. Ceftazidime/Avibactam among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021
2816. Comparative Effectiveness of Meropenem/Vaborbactam vs. Ceftazidime/Avibactam among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021 Open
Background Increasing rates of antimicrobial resistance have complicated the treatment of severe infections. Designated an “urgent threat” by the CDC, carbapenem-resistant Enterobacterales (CRE) lead to excess morbidity and mortality in mu…
View article: 2817. Outcomes of Timely vs. Delayed Meropenem/Vaborbactam Treatment of Infections with CRE among Adults Hospitalized in the US, 2019-2021
2817. Outcomes of Timely vs. Delayed Meropenem/Vaborbactam Treatment of Infections with CRE among Adults Hospitalized in the US, 2019-2021 Open
Background Carbapenem-resistant Enterobacterales (CRE) represent an urgent threat. Mortality rates associated with this pathogen approach 80%. Timely treatment of serious infections, even with highly resistant organisms, among hospitalized…
View article: What’s New in Antibiograms? Updating CLSI M39 Guidance with Current Trends
What’s New in Antibiograms? Updating CLSI M39 Guidance with Current Trends Open
A vast amount of antimicrobial susceptibility test (AST) data is generated from routine testing in diagnostic laboratories for the primary purpose of guiding clinicians in antimicrobial therapy decisions for their patients. However, there …
View article: The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities
The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities Open
Background: Antibiotic resistance is an evolving issue which requires constant review. Susceptibility breakpoints are revised in line with new microbiological and pharmacological data. Susceptibility breakpoints for carbapenems and Enterob…
View article: Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties
Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties Open
Background There is a need for improved antibiotic formulations for the treatment of acute bacterial skin and soft structure infection (ABSSSI), especially with the rise of antimicrobial resistance among Gram-positive bacteria. A new formu…
View article: Antimicrobial Management of Respiratory Infections in Severe Acute Respiratory Syndrome Coronavirus 2 Patients: Clinical and Antimicrobial Stewardship Programs Conundrums
Antimicrobial Management of Respiratory Infections in Severe Acute Respiratory Syndrome Coronavirus 2 Patients: Clinical and Antimicrobial Stewardship Programs Conundrums Open
The role of empirical and even directed antimicrobial management of patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is problematic; antibiotics are used frequently among these patients to t…
View article: Minocycline Intravenous for the Treatment of Serious Infections Due to Gram-Negative Nonpseudomonal Bacteria, Including Stenotrophomonas maltophilia, Acinetobacter baumannii, and Burkholderia cepacia
Minocycline Intravenous for the Treatment of Serious Infections Due to Gram-Negative Nonpseudomonal Bacteria, Including Stenotrophomonas maltophilia, Acinetobacter baumannii, and Burkholderia cepacia Open
Background Data on the role of minocycline intravenous (IV) in the treatment of serious gram-negative infections under real-world conditions are sparse. This study sought to provide evidence of real-world practices, including outcomes and …
View article: Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting
Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting Open
Objective Hospital admission is a key cost driver among patients with skin and soft tissue infections (SSTI). Data suggest that many SSTI patients are hospitalized unnecessarily and can be managed effectively and safely in an outpatient se…
View article: The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections
The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections Open
Background Oritavancin (ORI) is a long-acting lipoglycopeptide indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible Gram-positive (G…
View article: 443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections
443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections Open
Background Oritavancin (ORI) is a long-acting lipoglycopeptide antibiotic indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible Gram-p…
View article: Antibiotic Breakpoints: How Redefining Susceptibility Preserves Efficacy and Improves Patient Care.
Antibiotic Breakpoints: How Redefining Susceptibility Preserves Efficacy and Improves Patient Care. Open
Carbapenems are a primary treatment for infections from multidrug-resistant bacterial pathogens. To maintain their efficacy and control the emergence of further resistance, breakpoints that correspond to recommended doses with appropriate …
View article: 1928. Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting
1928. Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting Open
BACKGROUND: Hospital admission is a key cost driver in ABSSSI patients. Data suggest many ABSSSI patients are unnecessarily hospitalized and can be effectively and safely managed as outpatient (OP) at substantially lower cost. ORI a single…
View article: 1181. Use of the Combination Antibiogram in the Era of MDR Gram-Negative Pathogens
1181. Use of the Combination Antibiogram in the Era of MDR Gram-Negative Pathogens Open
Background Combinations of two or more antimicrobial agents are frequently used in empiric therapy regimens to ensure at least one agent demonstrates activity against suspected pathogens. A combination antibiogram can assess the increase i…
View article: A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program
A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program Open
Background Oritavancin is a lipoglycopeptide used in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. To characterize its use in patients in the postapproval setting, a patient registry was developed…
View article: Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials
Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials Open
Background The objective of this analysis was to evaluate the efficacy and safety of oritavancin compared with vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSIs) who received treatment in the outpatie…